You’ve probably heard of Ozempic or Wegovy. These are injectable drugs which have develop into household names for weight reduction and diabetes.
Now, researchers are investigating whether these drugs, GLP-1 agonists or GLP-1 drugs, can treat every part from cancer and mental illness to depression, addiction and endometriosis.
Some of the outcomes are really interesting. Others are being oversold. Here’s what the science actually says.
First, how do these drugs work?
GLP-1 (glucagon-like peptide-1) is a hormone that your intestines naturally release after you eat. This prompts your pancreas to provide insulin and signal to your brain that you just are full. These drugs mimic this hormone.
But GLP-1 receptors aren’t just within the gut. They are present in the center, kidney, liver and brain. That’s why scientists think these drugs can do greater than just control weight.
Where the evidence is already solid.
In addition to diabetes and obesity, GLP-1 drugs have now received regulatory approval in several latest areas.
Oh Trial of over 17,000 people Semaglutide (the lively drug in Ozempic/Wegovy) reduced the danger of significant heart attacks and strokes by 20%, even in people without diabetes.
In one A trial of approximately 1200 patientsSemaglutide outperformed placebo in treating a variety of advanced liver disease.
Tirzepatide (Mounjaro) has also been shown to be outstanding. Reduce the severity of sleep deprivation.mostly because weight reduction puts less pressure on the airways.
GLP-1s and cancer: promising but no clinical trial evidence.
Obesity is a risk factor for not less than 13 CancerTherefore weight reduction using GLP-1 drugs may also be expected to limit the danger of cancer. It was shown in a study Of the 86,000 adults with obesity. It found that GLP-1 users had a 17 percent lower risk of cancer.
New data suggests that GLP-1 users were also less more likely to have cancer spread to other organs, but this work has yet to be confirmed by other researchers. The anti-inflammatory effects of those drugs, which appear to work independently of weight reduction, may play a task.
However, there haven’t yet been any well-controlled clinical trials that establish a link between GLP-1 drugs and cancer prevention.
Endometriosis: Early but promising signs
Endometriosis affects approx One in ten women of reproductive age. This is where tissue just like the lining of the uterus grows outside the uterus.
Because GLP-1 receptors are also present in reproductive tissues, these drugs have shown promise in improving symptoms. A survey of 161 women support it.
But, like cancer, there aren’t any randomized human trials.
Haberdoedas/Unsplash
Addiction and smoking
GLP-1 receptors are concentrated within the reward pathways of the brain. These same circuits generate cravings for alcohol, nicotine, and medicines.
Analysis of More than 1.3 million people GLP-1 users had significantly lower rates of opioid overdose and alcohol intoxication.
A randomized trial Semaglutide intake was found to be lower in individuals with alcohol use disorders.
quickly Smoking cessation trials are also encouraging.
The brain: a less clear picture for GLP-1 therapy
This is where the story gets really complicated.
There are real biological the reason why GLP-1 drugs may help with neurodegeneration and brain damage. They reduce brain inflammation, interact with dopamine (a stimulating brain chemical) and support the gut-brain axis (the communication network that carries signals from the gut to the brain).
However, current clinical evidence is conflicting.
For Alzheimer’s disease, The researchers gave 204 participants Liraglutide (a GLP-1 that predates Ozempic) with mild-to-moderate disease and measured how much their brain volume was reduced. Drug users showed significantly less shrinkage in key brain regions, including their temporal lobes and overall gray matter.
However, one A large phase 3 trial Oral semaglutide was found to be ineffective in reducing clinical disease progression.
Similarly, exenatide (one other first GLP-1) showed no evidence of disease modification in a Phase 3 Parkinson’s disease trial.
For mental health, current evidence can be mixed. A meta-analysis And Large group studies showed a major reduction in depression and anxiety scores in GLP-1 users.
But a unique one Observational study It found that folks on these drugs were almost twice as more likely to develop major depression.
Another one Paper found that individuals with a genetic predisposition to low dopamine levels could also be at greater risk of depression and suicidal thoughts on these drugs.
are also Case reports Serious psychotic episodes appear inside weeks of starting treatment.
We still do not know who these drugs will help, and who they may seriously harm.
Which we must be careful about.
Importantly, most latest uses of those drugs haven’t yet been tested in adequate clinical trials. Large real-world studies are useful, but they can’t rule out essential confounding aspects. This implies that the consequences will be attributable to external influences.
For example, most large GLP-1 trials have enrolled individuals with obesity or diabetes. Individuals with mental health conditions, neurodegenerative diseases, or addictions were largely excluded. Yet, it’s these same populations which are now being considered for treatment.
Long-term effects are also unknown. Oh Study of over 200,000 patients The risk of drug-induced pancreatitis (malignant inflammation of the pancreas) was found to be 2-2.5 times higher.
Rapid weight reduction also destroys lean muscle, not only fat, affecting strength and metabolism, especially in older adults.
Studies have also indicated that these drugs result in A Thyroid cancer riskA warning sign on the drug label, however the evidence is overwhelming Contradictory.
Time and more research will tell, but there are real safety concerns in regards to the widespread use of those drugs.
So, while the science here is genuinely interesting, we must always proceed to approach it with informed caution.